Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease

Leukemia Research

Volumn 33, Issue 3, 2009, Pages 384-390

  Qin, YaZhen ^a   Zhu, HongHu ^a   Jiang, Bin ^a   Li, JinLan ^a   Lu, XiJing ^a   Li, LingDi ^a   Ruan, GuoRui ^a   Liu, YanRong ^a   Chen, ShanShan ^a   Huang, XiaoJun ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Minimal residual disease; PRAME; Real time quantitative PCR; WT1

Indexed keywords

ANTIGEN; COMPLEMENTARY DNA; MOLECULAR MARKER; PRAME ANTIGEN; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CELL ISOLATION; CHILD; FEMALE; FOLLOW UP; FUSION GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BONE MARROW; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS; YOUNG ADULT;

EID: 58549105899     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.08.026     Document Type: Article

References (27)

1. Call K.M., Glaser T., Ito C.Y., Bukler A.J., Pelletier J., Haber D.A., et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60 (1990) 509-520
2. Haber D.A., Buckler A.J., Glaser T., Call K.M., Pelletier J., Sohn R.L., et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 61 (1990) 1257-1269
3. Yang L., Han Y., Suarez Saiz F., and Minden M.D. A tumor suppressor and oncogene: the WT1 story. Leukemia 21 (2007) 868-876
4. Cilloni D., Gottardi E., De Micheli D., Serra A., Volpe G., Messa F., et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16 (2002) 2115-2121
5. Ikeda H., Lethe B., Lehmann F., van Baren N., Baurain J.F., de Smet C., et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6 (1997) 199-208
6. Tajeddine N., Gala J.L., Louis M., Van Schoor M., Tombal B., and Gailly P. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res 65 (2005) 7348-7355
7. Epping M.T., Wang L., Edel M.J., Carlee L., Hernandez M., and Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122 (2005) 835-847
8. Matsushita M., Ikeda H., Kizaki M., Okamoto S., Ogasawara M., Ikeda Y., et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 112 (2001) 916-926
9. Steinbach D., Hermann J., Viehmann S., Zintl F., and Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 133 (2002) 118-123
10. Greiner J., Ringhoffer M., Taniguchi M., Li L., Schmitt A., Shiku H., et al. transcript expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 108 (2004) 704-711
11. Paydas S., Tanriverdi K., Yavuz S., Disel U., Baslamisli F., and Burgut R. PRAME transcript levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol 79 (2005) 257-261
12. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 17 (2003) 2318-2357
13. Beillard E., Pallisgaard N., van der Velden V.H., Bi W., Dee R., van der Schoot E., et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program. Leukemia 17 (2003) 2474-2486
14. Tamaki H., Mishima M., Kawakami M., Tsuboi A., Kim E.H., Hosen N., et al. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). Int J Hematol 78 (2003) 349-356
15. Qin Y.Z., Liu Y.R., Zhu H.H., Li J.L., Ruan G.R., Zhang Y., et al. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response. Int J Lab Hematol 30 (2008) 317-323
16. Trka J., Kalinová M., Hrusák O., Zuna J., Krejcí O., Madzo J., et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 16 (2002) 1381-1389
17. Ostergaard M., Olesen L.H., Hasle H., Kjeldsen E., and Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients-results from a single-centre study. Br J Haematol 125 (2004) 590-600
18. Spanaki A., Perdikogianni C., Linardakis E., and Kalmanti M. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia. Leuk Res 31 (2007) 639-642
19. Bergmann L., Miething C., Maurer U., Brieger J., Karakas T., Weidmann E., et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90 (1997) 1217-1225
20. Barragan E., Cervera J., Bolufer P., Ballester S., Martin G., Fernandez P., et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 89 (2004) 926-933
21. Schmid D., Heinze G., Linnerth B., Tisljar K., Kusec R., Geissler K., et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 11 (1997) 639-643
22. Hamalainen M.M., Kairisto V., Juvonen V., Johansson J., Auren J., Kohonen K., et al. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Eur J Haematol 80 (2008) 201-207
23. Tajeddine N., Louis M., Vermylen C., Gala J.L., Tombal B., and Gailly P. Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo. Leukemia Lymphoma 23 (2008) 1-9
24. Greiner J., Ringhoffer M., Simikopinko O., Szmaragowska A., Huebsch S., Maurer U., et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol 28 (2000) 1413-1422
25. Gaiger A., Schmid D., Heinze G., Linnerth B., Greinix H., Kalhs P., et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 12 (1998) 1886-1894
26. Gorello P., Cazzaniga G., Aiberti F., Dell'Oro M.G., Gottardi E., Specchia G., et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 20 (2006) 1103-1108
27. Cilloni D., Messa F., Arruga F., Defilippi I., Gottardi E., Fava M., et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 93 (2008) 921-924